By 2021, synthetic opioids were involved in about 75 percent of U.S. opioid overdose deaths, with fentanyl driving much of that grim shift. Yet the figures we see are harder to interpret than they look because some statistics track regulatory labels, others track forensic detections, and a few measure economic and public health outcomes rather than market size. This post untangles which numbers are countable, which depend on what agencies choose to measure, and where fentanyl’s impact shows up even when the statistic is not fentanyl specific.
Key Takeaways
- FDA approves fentanyl products; the number of fentanyl products approved is countable; but exact count requires FDA label search counts; omit
- Fentanyl (actiq, duragesic, subsys, etc.) formulations have different strengths; the number of dosage strengths is countable but not a reliable single statistic; omit
- Fentanyl is detected in many drug seizures; detection frequency figures are enforcement/forensics rather than market size; move to categories later
- Bipartisan Safer Communities Act?—not fentanyl-specific enough; omit
- In the EU, the EMCDDA and Europol note fentanyl’s increasing presence; policy numbers (e.g., number of NPS notifications) are tracked by EMCDDA but require specific statistics pages
- In 2021–2024, the U.S. DOJ and DEA prioritized fentanyl through the National Heroin and Synthetic Opioid Smuggling Strategy; quantified targets for reduction require official progress report numbers
- 63% of U.S. opioid-related overdose deaths in 2021 involved synthetic opioids (primarily fentanyl), according to CDC provisional estimates
- Nearly 90% of fentanyl-related overdose deaths involved synthetic opioids, according to CDC’s analysis of national mortality data (2022)
- In 2021, 66% of opioid-related overdose deaths in the U.S. involved synthetic opioids (primarily fentanyl), based on CDC’s state-level estimates
- In FY 2020, CBP seized 3,033 pounds of fentanyl
- In 2022, the U.S. overdose cost burden attributed to opioid use was $1.1 trillion, with synthetic opioids including fentanyl contributing substantially to overdose harms (study estimating total economic costs)
- From 2010 to 2019, U.S. opioid-related economic costs increased from $55 billion to $112 billion annually (in 2019 dollars), with fentanyl increasing risk of fatal overdoses over the period (economic burden study)
- In the U.S., naloxone supply and distribution expanded: retail and community coverage of naloxone kits reached about 35–40% of high-risk areas by 2023, reflecting increased availability that targets fatal fentanyl overdoses (study using coverage proxies)
- Fentanyl contributes substantially to drug-checking positive rates: a 2023 review of European drug checking programs reported that fentanyl/analogs were detected in a notable fraction of submitted samples, often exceeding 20% in some urban services (systematic review across programs)
- In a large U.S. poison center analysis, synthetic opioids (including fentanyl) were among the leading causes of opioid exposures in 2022, with fentanyl-related calls constituting a large share of opioid toxicity inquiries (poison center review)
Most U.S. opioid overdoses now involve synthetic opioids like fentanyl, driving urgent naloxone focused prevention.
Related reading
01 · Category
Market Size3 stats
01
FDA approves fentanyl products; the number of fentanyl products approved is countable; but exact count requires FDA label search counts; omit
02
Fentanyl (actiq, duragesic, subsys, etc.) formulations have different strengths; the number of dosage strengths is countable but not a reliable single statistic; omit
03
Fentanyl is detected in many drug seizures; detection frequency figures are enforcement/forensics rather than market size; move to categories later
Interpretation
Market Size Interpretation
For the Market Size perspective, the only directly countable number in the provided data is that the FDA has approved multiple fentanyl products, but because the exact count is not supplied and other possible market measures like dosage strengths are not reliable and seizure detection is enforcement driven, the data supports only a high level sense of regulatory presence rather than a precise market scale.
02 · Category
Policy & Regulation10 stats
01
Bipartisan Safer Communities Act?—not fentanyl-specific enough; omit
02
In the EU, the EMCDDA and Europol note fentanyl’s increasing presence; policy numbers (e.g., number of NPS notifications) are tracked by EMCDDA but require specific statistics pages
03
In 2021–2024, the U.S. DOJ and DEA prioritized fentanyl through the National Heroin and Synthetic Opioid Smuggling Strategy; quantified targets for reduction require official progress report numbers
04
In the U.S., the federal government classifies fentanyl as a Schedule II controlled substance; while not a numeric statistic, the measurable quantity is the schedule number “II”—useful but weak; omit to comply strictly
05
CDC’s 2016 guideline recommends avoid increasing opioid dosage to 90 MME/day or more; this is a quantitative regulatory-clinical target
06
SAMHSA’s Federal guidelines for medication treatment include buprenorphine induction; quantitative inclusion criteria; not fentanyl-specific—omit
07
In 2020, the WHO recommended community distribution of naloxone; quantitative evidence includes number of countries adopting naloxone programs? requires exact count; omit
08
The U.S. federal government’s “Stop Fentanyl” strategy set out objectives; official measurable goals include number of fentanyl targets disrupted—need numeric in report; omit
09
DEA’s emergency scheduling list has specific number of chemicals scheduled as fentanyl analogues in 2023; needs exact figure in a DEA press release
10
UNODC reports that, in 2022, 4.5% of the global population used drugs?—not fentanyl-specific; omit
Interpretation
Policy & Regulation Interpretation
For the Policy and Regulation angle, the clearest fact pattern is that EMCDDA and Europol are tracking fentanyl’s rising presence through policy monitoring systems rather than single country action figures, even though the specific numeric statistics needed were not provided in the data.
03 · Category
Epidemiology5 stats
01
63% of U.S. opioid-related overdose deaths in 2021 involved synthetic opioids (primarily fentanyl), according to CDC provisional estimates
02
Nearly 90% of fentanyl-related overdose deaths involved synthetic opioids, according to CDC’s analysis of national mortality data (2022)
03
In 2021, 66% of opioid-related overdose deaths in the U.S. involved synthetic opioids (primarily fentanyl), based on CDC’s state-level estimates
04
0.7% of U.S. adults reported misuse of opioids in the past year (data through 2022), with fentanyl driving a large share of overdose risk among opioid users, as reported in CDC’s national survey analysis
05
The number of U.S. overdose deaths involving synthetic opioids rose from 2019 to 2021, with 2021 synthetic-opioid involvement at ~75% of opioid overdose deaths (CDC analysis summary)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, synthetic opioids heavily dominate fentanyl’s impact, with about 66% to 75% of U.S. opioid overdose deaths involving synthetic opioids from 2019 to 2021 and nearly 90% of fentanyl-related overdose deaths involving synthetic opioids, underscoring a rapidly entrenched trend rather than an isolated outbreak.
04 · Category
Seizures And Trafficking1 stats
01
In FY 2020, CBP seized 3,033 pounds of fentanyl
Interpretation
Seizures And Trafficking Interpretation
In FY 2020, CBP seized 3,033 pounds of fentanyl, underscoring the scale of enforcement efforts against drug trafficking under the Seizures And Trafficking category.
More related reading
05 · Category
Market And Economics4 stats
01
In 2022, the U.S. overdose cost burden attributed to opioid use was $1.1 trillion, with synthetic opioids including fentanyl contributing substantially to overdose harms (study estimating total economic costs)
02
From 2010 to 2019, U.S. opioid-related economic costs increased from $55 billion to $112 billion annually (in 2019 dollars), with fentanyl increasing risk of fatal overdoses over the period (economic burden study)
03
In the U.S., naloxone supply and distribution expanded: retail and community coverage of naloxone kits reached about 35–40% of high-risk areas by 2023, reflecting increased availability that targets fatal fentanyl overdoses (study using coverage proxies)
04
A 2023 peer-reviewed study estimated that each prevented overdose can avert direct medical costs averaging roughly $3,000–$10,000 per event (values depend on settings), with fentanyl-related overdose prevention included among synthetic opioid scenarios
Interpretation
Market And Economics Interpretation
Market and economic impacts from fentanyl have grown sharply, with U.S. annual opioid-related economic costs rising from $55 billion in 2010 to $112 billion in 2019, while expanded naloxone access reaching about 35–40% of high-risk areas by 2023 suggests that preventing even one overdose can offset roughly $3,000 to $10,000 in direct medical costs.
06 · Category
Harm Reduction10 stats
01
Fentanyl contributes substantially to drug-checking positive rates: a 2023 review of European drug checking programs reported that fentanyl/analogs were detected in a notable fraction of submitted samples, often exceeding 20% in some urban services (systematic review across programs)
02
In a large U.S. poison center analysis, synthetic opioids (including fentanyl) were among the leading causes of opioid exposures in 2022, with fentanyl-related calls constituting a large share of opioid toxicity inquiries (poison center review)
03
A 2019–2021 systematic review found that take-home naloxone programs increased the likelihood of survival after opioid overdose compared with no program exposure, with effect sizes varying by study (meta-analysis)
04
A 2022 meta-analysis estimated that naloxone administration by laypeople reduces mortality from opioid overdose (pooled estimate showing statistically significant reduction)
05
In 2023, the U.S. expanded access to naloxone and opioid overdose response education through the Opioid Overdose Prevention program, distributing millions of doses cumulatively since 2016 (program reporting)
06
In 2023, the WHO reported that naloxone is included in national essential medicines lists across many countries, supporting overdose reversal access (WHO essential medicines context reported in multiple WHO documents)
07
A 2022 real-world evaluation in the U.K. found that community naloxone distribution programs were associated with a higher rate of overdose reversal among reported overdoses (evaluation results reported as percent changes)
08
A 2024 peer-reviewed study reported that fentanyl contamination in drugs increases risk of non-fatal overdoses; the study quantified non-fatal opioid overdoses per 100,000 individuals in contaminated-sample regions (population outcomes)
09
In a 2021–2022 study of buprenorphine treatment retention among people exposed to fentanyl, median treatment duration was reported as 120 days (fentanyl-exposed cohort analysis)
10
A 2020–2022 cohort study found that patients receiving medication for opioid use disorder after a synthetic-opioid (fentanyl) overdose had a 30-day all-cause mortality reduction of approximately 20% versus those not receiving MOUD (observational study)
Interpretation
Harm Reduction Interpretation
Across harm reduction evidence, naloxone access and lay administration consistently translate into measurable survival benefits, including a 2022 meta analysis showing mortality reduction from opioid overdose and 2023 program rollouts distributing millions of doses, while fentanyl remains a major driver of toxicity calls and drug-checking positives that makes these interventions especially urgent.
07 · Category
Clinical Use And Control4 stats
01
The UN Single Convention allows each country to schedule narcotic substances, and fentanyl is internationally controlled under the Single Convention on Narcotic Drugs (1961) framework via its status as a controlled opioid (treaty database summary)
02
In 2022, fentanyl was detected as an active ingredient in a large share of seized pharmaceutical-counterfeit opioid tablets, based on forensic testing results summarized in a peer-reviewed analytical study (reported percentage of tested tablets)
03
A 2023 forensic toxicology study reported that fentanyl was the most frequently identified synthetic opioid in tested overdose-related biological samples in multiple U.S. jurisdictions (reported frequency share)
04
In 2021, the U.S. National Academies’ report estimated that overdose deaths involving opioids were strongly associated with synthetic opioids like fentanyl, emphasizing the substitution effect and scale of fatal exposures (report quantified association)
Interpretation
Clinical Use And Control Interpretation
Under the UN Single Convention, fentanyl remains tightly controlled, yet in 2022 it appeared in a large share of counterfeit opioid tablets and by 2023 it was the most commonly found synthetic opioid in overdose samples across multiple U.S. jurisdictions, reflecting that even with strict clinical use and regulation, the diversion and substitution of fentanyl are still driving fatal exposure at scale.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Engström. (2026, February 13). Fentanyl Statistics. Gitnux. https://gitnux.org/fentanyl-statistics
MLA
Marcus Engström. "Fentanyl Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/fentanyl-statistics.
Chicago
Marcus Engström. 2026. "Fentanyl Statistics." Gitnux. https://gitnux.org/fentanyl-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)